Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02677844 · ClinicalTrials.gov registry record · Phase 1
A Study of Abemaciclib in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT02677844 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 35 participants.
The verdict
NCT02677844, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purposes of this study are to determine: * The effect of single increasing doses of the study drug, abemaciclib, on healthy participants. * The relationship between the amount of abemaciclib and the electrical tracing of the heart rhythm when abemaciclib is given. * How much abemaciclib is found in the bloodstream and how long the body takes to get rid of it. Information about any side effects that occur will be collected. The study will enroll two groups (cohorts) of participants. Each group will complete 4 study periods. This study is expected to last about 3 months. Screening may occur up to 28 days prior to enrollment. All participants will undergo a follow-up assessment approximately 21 days after administration of their final dose of study drug.
Interventions
- DRUG Placebo
- DRUG Abemaciclib
- DRUG Loperamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02677844
The ClinicalTrials.gov registry entry for NCT02677844 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02677844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02677844 about?
NCT02677844 is a clinical study titled "A Study of Abemaciclib in Healthy Participants". The purposes of this study are to determine: * The effect of single increasing doses of the study drug, abemaciclib, on healthy participants. * The relationship between the amount of abemaciclib and the electrical tracing of the heart rhythm when abemaciclib is given. * How much abemaciclib is foun...
What is the current status of trial NCT02677844?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2016-02. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02677844?
The interventions under investigation include: Placebo (DRUG), Abemaciclib (DRUG), Loperamide (DRUG).
Who is sponsoring clinical trial NCT02677844?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.